Willemse PH - Search Results

1

Cell biological markers of drug resistance in ovarian carcinoma.

van der Zee AG, Hollema HH, de Bruijn HW, Willemse PH, Boonstra H, Mulder NH, Aalders JG, de Vries EG. van der Zee AG, et al. Among authors: willemse ph. Gynecol Oncol. 1995 Aug;58(2):165-78. doi: 10.1006/gyno.1995.1205. Gynecol Oncol. 1995. PMID: 7622101 Review.

2

Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.

Hofstra LS, Bos AM, de Vries EG, van der Zee AG, Willemsen AT, Rosing H, Beijnen JH, Mulder NH, Aalders JG, Willemse PH. Hofstra LS, et al. Among authors: willemse ph. Gynecol Oncol. 2002 Jun;85(3):517-23. doi: 10.1006/gyno.2002.6665. Gynecol Oncol. 2002. PMID: 12051884

3

A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.

De Vos FY, Bos AM, Schaapveld M, de Swart CA, de Graaf H, van der Zee AG, Boezen HM, de Vries EG, Willemse PH. De Vos FY, et al. Among authors: willemse ph. Gynecol Oncol. 2005 Apr;97(1):60-7. doi: 10.1016/j.ygyno.2004.11.052. Gynecol Oncol. 2005. PMID: 15790438 Clinical Trial.

4

Long-term survival after vinblastine, bleomycin, and cisplatin treatment in patients with germ cell tumors of the ovary: an update.

Willemse PH, Aalders JG, Bouma J, Mulder NH, Verschueren RC, de Vries EG, Sleijfer DT. Willemse PH, et al. Gynecol Oncol. 1987 Nov;28(3):268-77. doi: 10.1016/0090-8258(87)90172-7. Gynecol Oncol. 1987. PMID: 2445635

5

Role of an early second-look laparotomy in ovarian cancer.

van Lith JM, Bouma J, Aalders JG, Boonstra H, Sleijfer DT, Willemse PH. van Lith JM, et al. Among authors: willemse ph. Gynecol Oncol. 1989 Nov;35(2):255-8. doi: 10.1016/0090-8258(89)90055-3. Gynecol Oncol. 1989. PMID: 2807020

6

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.

van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG. van der Zee AG, et al. Among authors: willemse ph. J Clin Oncol. 1995 Jan;13(1):70-8. doi: 10.1200/JCO.1995.13.1.70. J Clin Oncol. 1995. PMID: 7799045

7

Effect of low-dose oral etoposide on serum CA-125 in patients with advanced epithelial ovarian cancer.

de Jong RS, Hofstra LS, Willemse PH, de Bruijn HW, de Vries EG, Boonstra H, Mulder NH. de Jong RS, et al. Among authors: willemse ph. Gynecol Oncol. 1997 Aug;66(2):197-201. doi: 10.1006/gyno.1997.4760. Gynecol Oncol. 1997. PMID: 9264562 Clinical Trial.

8

Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.

Arts HJ, Willemse PH, Tinga DJ, de Vries EG, van der Zee AG. Arts HJ, et al. Among authors: willemse ph. Gynecol Oncol. 1998 Apr;69(1):32-5. doi: 10.1006/gyno.1998.4968. Gynecol Oncol. 1998. PMID: 9570995

9

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.

Mourits MJ, Van der Zee AG, Willemse PH, Ten Hoor KA, Hollema H, De Vries EG. Mourits MJ, et al. Among authors: willemse ph. Gynecol Oncol. 1999 Apr;73(1):21-6. doi: 10.1006/gyno.1998.5316. Gynecol Oncol. 1999. PMID: 10094875

10

Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis.

Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, Van der Zee AG. Arts HJ, et al. Among authors: willemse ph. Int J Cancer. 1999 Jun 21;84(3):234-8. doi: 10.1002/(sici)1097-0215(19990621)84:3<234::aid-ijc6>3.0.co;2-9. Int J Cancer. 1999. PMID: 10371339

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters